Aptinyx’s Development Pipeline
Aptinyx’s proprietary chemistry platform has yielded numerous small-molecule modulators of N-methyl-D-aspartate (NMDA) receptors. A number of these molecules have advanced into clinical development as drug candidates for the treatment of various brain and nervous system disorders. In studies to date, they have demonstrated high oral bioavailability, diverse NMDA receptor subtype binding profiles and differentiated efficacy. Aptinyx’s small-molecule compounds bind to a distinct, recently discovered site on the NMDA receptor to modulate NMDA-receptor channel opening and enhance synaptic plasticity. This mechanism is distinct from any other therapies, emerging or marketed, for multiple challenging neurologic disorders.